Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Tesamorelin Therapy to Enhance Axonal Regeneration, Minimize Muscle Atrophy, and Improve Functional Outcomes Following Peripheral Nerve Injury

Trial Profile

Tesamorelin Therapy to Enhance Axonal Regeneration, Minimize Muscle Atrophy, and Improve Functional Outcomes Following Peripheral Nerve Injury

Recruiting
Phase of Trial: Phase II

Latest Information Update: 15 Feb 2019

At a glance

  • Drugs Tesamorelin (Primary)
  • Indications Peripheral nerve injuries
  • Focus Therapeutic Use
  • Most Recent Events

    • 12 Jul 2018 Status changed from not yet recruiting to recruiting.
    • 22 May 2018 Planned initiation date changed from 1 Mar 2018 to 1 Jun 2018.
    • 15 Feb 2018 Planned initiation date changed from 1 Jul 2017 to 1 Mar 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top